Feature | July 17, 2012| Dave Fornell

An Introduction to Atherectomy Systems

The Bayer-Medrad Navitus atherectomy catheter has two cutting surfaces and integrated aspiration.

Atherectomy devices are used in the cath lab to debulk lesions by cutting or laser ablating plaque, calcium and tissue hyperplasia from vessel walls, allowing recanalization of the vessel lumen as an end in itself, or in preparation for stenting. While some devices have an indication for the coronaries, the primary use of these devices is for peripheral artery disease (PAD) in the legs. 

Healthcare providers are increasingly viewing PAD as a progressive, chronic disease that requires a continuum of treatment, where few patients are treated only once.  Many are treated to restore flow whenever the disease re-occludes a vessel, or a new vessel develops a blockage.  The goal is to improve quality of life and prevent amputation. 

Treatments that restore bloodflow without reducing the ability to treat the vessel in the future are better suited for PAD.  Atherectomy is seen by many as an ideal therapy for PAD because it can restore flow while removing the plaque burden and does not leave behind a permanent obstacle to future treatments, such as a stent. Stenting in the legs leads to frequent restenosis or fractured stent struts, and can be problematic or prevent repeat interventional or open surgical repairs.

Cost of treatment is always a concern for both reimbursement and institutions. Atherectomy may be a less costly approach to PAD over the life of a patient than open surgery or ballooning and stenting.  Within the atherectomy market, the vendors must demonstrate both economic advantages and procedural success. The total cost (including the number) of devices needed for a procedure, the duration of lumen patency and reduction of side effects that require additional treatments influence use of these technologies.

Cardiovascular Systems Inc. (CSI) recently shared 12-month data from the COMPLIANCE 360° study of severely calcified above-the-knee lesions. The prospective study of 50 patients (with 65 lesions) at nine U.S. sites randomized patients equally to balloon angioplasty alone versus the Diamondback Orbital Atherectomy System with adjunctive ballooning.  The study showed that avoiding stents and reducing restenosis saved money. The approximate incremental cost savings of the atherectomy group at six months was $5,264 per additional acute adjunctive stenting or restenosis avoided.  The study also found the angioplasty arm required bailout stenting in 84 percent of the procedures to achieve results equivalent to the Diamondback arm. 

There is increasing interest in atherectomy treatments in vessels below the knee. Successfully recanalizing arteries to the ankle and foot can reduce pain, restore mobility and reverse ulceration, which may have a major impact on the costs of chronic wound care in lower extremities.

There was a setback for coronary atherectomy with the results of the ROTAXUS (A Prospective, Randomized Trial of High-Speed Rotational Atherectomy Prior to Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary Lesions) trial, presented at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) symposium. The trial found the process was not superior to standard balloon angioplasty and decreased the efficacy of the stent in reducing new tissue growth within the blood vessel.

Drug-eluting stents (DES) are liberally used in complex lesions. Heavily calcified stenoses have not been adequately studied, and form a challenge for immediate and late outcomes. Rotational atherectomy has been shown to effectively modify calcified plaques and facilitate stent delivery and expansion. In patients with complex calcified lesions, rotablation followed by DES seems a rational combination, but there was a lack of evidence prior to the ROTAXUS trial. 

 

Comparing Scanners 

This article served as an introduction to an atherectomy system comparison chart in the July-August 2012 print issue of DAIC. The chart can be accessed in the comparison chart tab at the top of the screen, or at www.dicardiology.com/comparison-charts?t=Atherectomy+Systems  The chart included the following vendors: 

 

Bayer HealthCare (Medrad) - www.interventional.bayer.com

Boston Scientific - www.bostonscientific.com

Covidien - www.turbohawkdevice.com

Cardiovascular Systems Inc. (CSI) - www.csi360.com

Spectranetics - www.spectranetics.com

Related Content

radial access, transradial
Feature | Radial Access| May 27, 2016 | Dave Fornell
The use of transradial artery vascular access for percutaneous coronary intervention (PCI) in the United States has s
Toshiba, Infinix 4-D CT, first U.S. install, Arkansas cancer center
News | CT Angiography (CTA)| May 26, 2016
Cancer patients at the Carti Cancer Center, Conway, Ark., now have access to the latest innovation in diagnostic...
cath lab, radiation exposure, glocoma
Feature | Radiation Dose Management| May 26, 2016 | Dave Fornell
May 27, 2016 — Radiation exposure to cath lab staff and physicians has seen growing concern in recent years, as the p
anticoagulants, U.S. market, Technavio, 2020, trends
News | Antiplatelet and Anticoagulation Therapies| May 25, 2016
Technavio’s latest report on the U.S. anticoagulants market provides an analysis on the most important trends expected...
IVPA, intravascular photoacoustic imaging, fatty arteries, Purdue, Shanghai

IVPA/IVUS imaging of a perfused fresh human right coronary artery dissected from an explanted heart. (A) IVPA image. (B) IVUS image. (C) Merged IVPA/IVUS image. The 1 mm scale bar applies to all panels.

News | Intravascular Imaging| May 25, 2016
A new imaging system known as intravascular photoacoustic (IVPA) imaging that produces three-dimensional images of the...
News | Cath Lab| May 24, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions took place May 4-7, 2016
HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
PCI, OFDI, OCT, optical coherence tomography, optimal frequency domain imaging, EuroPCR 2016 study
News | Intravascular Imaging| May 20, 2016
Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
St. Jude Medical, EuroPCR 2016 studies, FFR, LAAO, left atrial appendage occlusion, fractional flow reserve, Amplatzer
News | Cath Lab| May 19, 2016
St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016.
Overlay Init